期刊
TRENDS IN CANCER
卷 7, 期 9, 页码 847-862出版社
CELL PRESS
DOI: 10.1016/j.trecan.2021.05.001
关键词
-
类别
资金
- Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia, e Ensino Superior [2020.06638.BD]
- European Research Council [848325]
- European Research Council (ERC) [848325] Funding Source: European Research Council (ERC)
- Fundação para a Ciência e a Tecnologia [2020.06638.BD] Funding Source: FCT
The interest in nanomedicine for cancer theranostics has grown significantly, but overcoming physiological barriers in the tumor microenvironment remains a challenge. Intrinsic tumor genetic/phenotypic variations and heterogeneity present unique challenges in translating nanotechnology-based systems into clinically reliable therapies.
The interest in nanomedicine for cancer theranostics has grown significantly over the past few decades. However, these nanomedicines need to overcome several physiological barriers intrinsic to the tumor microenvironment (TME) before reaching their target. Intrinsic tumor genetic/phenotypic variations, along with intratumor heterogeneity, provide different cues to each cancer type, making each patient with cancer unique. This brings additional challenges in translating nanotechnology-based systems into clinically reliable therapies. To develop efficient therapeutic strategies, it is important to understand the dynamic interactions between TME players and the complex mechanisms involved, because they constitute invaluable targets to dismantle tumor progression. In this review, we discuss the latest nanotechnology-based strategies for cancer diagnosis and therapy as well as the potential targets for the design of future anticancer nanomedicines.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据